PXN and breast cancer: The potent tumor drug delivery ability of D/PSP@CQ/CaP can reduce the degradation of paxillin through autophagy inhibition to inhibit the autophagy-dependent breakdown of focal adhesions, thereby reducing the metastatic and growth ability of breast cancer [185].